The Valley Desk

NCT01460134 · Interventional trial

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Overall registry status Completed

Phase 1

Conditions Any T-cell Malignancy, Burkett's Lymphoma, CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Primary Lymphoma of the Central Nervous System, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov